Parainfluenza Virus Type 3 Expressing the Native or Soluble Fusion (F) Protein of Respiratory Syncytial Virus (RSV) Confers Protection from RSV Infection in African Green Monkeys

Tang, Roderick S.; MacPhail, Mia; Schickli, Jeanne H.; Kaur, Jasmine; Robinson, Christopher L.; Lawlor, Heather; Guzzetta, Jeanne M.; Spaete, Richard R.; Haller, Aurelia A.

doi:10.1128/jvi.78.20.11198-11207.2004

Cited by 83 publications

(58 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Together, hPIV3 and RSV are responsible for approximately one-third of all cases of pediatric respiratory diseases leading to hospitalization (Hall 2001). Despite the prevalence of hPIV3 and RSV infections in infants and young children, vaccines against these viruses remain unavailable (Tang et al 2004). …”

Section: Introductionmentioning

confidence: 99%

“…Next, they inserted the RSV F gene into the bovine/ human PIV3 vector backbone so that the resulting chimeric virus-named MEDI-534--expresses the RSV F protein (Tang et al 2003). MEDI-534 functioned as a live, attenuated, bivalent vaccine in animal studies: hamsters and non-human primates immunized with MEDI-534 produced both hPIV3 hemagglutination-inhibiting and RSV-neutralizing serum antibodies and these animals demonstrated protection from challenges with hPIV3 and RSV (Tang et al 2003(Tang et al , 2004.…”

Section: Introductionmentioning

confidence: 99%

“…Furthermore, regulatory authorities have provided guidelines on the use of Vero cells for viral vaccine production (WHO 1987a, b). Based on these advantages, MedImmune Vaccines selected the Vero cell line for propagating MEDI-534 (Tang et al 2003(Tang et al , 2004.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A serum-free Vero production platform for a chimeric virus vaccine candidate

Yuk¹,

Lin²,

Jiang³

et al. 2006

Cytotechnology

View full text Add to dashboard Cite

MedImmune Vaccines has engineered a live, attenuated chimeric virus that could prevent infections caused by parainfluenza virus type 3 (PIV3) and respiratory syncytial virus (RSV), causative agents of acute respiratory diseases in infants and young children. The work here details the development of a serum-free Vero cell culture production platform for this virus vaccine candidate. Efforts to identify critical process parameters and optimize culture conditions increased infectious virus titers by approximately 2 log 10 TCID 50 /ml over the original serum-free process. In particular, the addition of a chemically defined lipid concentrate to the preinfection medium along with the shift to a lower post-infection cultivation temperature increased virus titers by almost 100-fold. This improved serum-free process achieved comparable virus titers to the serum-supplemented process, and demonstrated consistent results upon scale-up: Vero cultures in roller bottles, spinner flasks and bioreactors reproducibly generated maximum infectious virus titers of 8 log 10 TCID 50 /ml.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A serum-free Vero production platform for a chimeric virus vaccine candidate

Yuk¹,

Lin²,

Jiang³

et al. 2006

Cytotechnology

View full text Add to dashboard Cite

show abstract

“…Viruses were obtained from ATCC (A Long, B 18537), Dr. Ralph Tripp (University of Georgia; strain A2), and Meridian Bioscience (strain Memphis 37) and propagated in HEp2 or HeLa cells (both from ATCC), as previously described (39). Plates were coated with viral preparations at 10 5 PFU/well in 100 mM carbonate buffer at pH 9.6 overnight at 4°C and blocked in 5% milk in PBS-Tween for 1 h at 25°C.…”

Section: Virus Stocks and Virus Binding Assaymentioning

confidence: 99%

Potent High-Affinity Antibodies for Treatment and Prophylaxis of Respiratory Syncytial Virus Derived from B Cells of Infected Patients

Collarini

Lee

Foord

et al. 2009

The Journal of Immunology

111

View full text Add to dashboard Cite

Native human Abs represent attractive drug candidates; however, the low frequency of B cells expressing high-quality Abs has posed a barrier to discovery. Using a novel single-cell phenotyping technology, we have overcome this barrier to discover human Abs targeting the conserved but poorly immunogenic central motif of respiratory syncytial virus (RSV) G protein. For the entire cohort of 24 subjects with recent RSV infection, B cells producing Abs meeting these stringent specificity criteria were rare, <10 per million. Several of the newly cloned Abs bind to the RSV G protein central conserved motif with very high affinity (Kd 1–24 pM). Two of the Abs were characterized in detail and compared with palivizumab, a humanized mAb against the RSV F protein. Relative to palivizumab, the anti-G Abs showed improved viral neutralization potency in vitro and enhanced reduction of infectious virus in a prophylaxis mouse model. Furthermore, in a mouse model for postinfection treatment, both anti-G Abs were significantly more effective than palivizumab at reducing viral load. The combination of activity in mouse models for both prophylaxis and treatment makes these high-affinity human-derived Abs promising candidates for human clinical testing.

show abstract

“…Because these pathogens belong to same RNA virus family Paramyxovirus and are responsible for respiratory disease in mostly children and adults of similar ages, we investigate whether interactions (either immunological or ecological) among them are the primary drivers of their epidemic patterns. In fact, there are previous theoretical and empirical studies that discuss interactions among these respiratory viruses (35,36). Understanding the factors that regulate epidemiological patterns and predicting the seasonal abundance of these viruses are central to their effective management.…”

mentioning

confidence: 99%

Cross-immunity between strains explains the dynamical pattern of paramyxoviruses

Bhattacharyya

Gesteland

Korgenski

et al. 2015

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Viral respiratory tract diseases pose serious public health problems. Our ability to predict and thus, be able to prepare for outbreaks is strained by the complex factors driving the prevalence and severity of these diseases. The abundance of diseases and transmission dynamics of strains are not only affected by external factors, such as weather, but also driven by interactions among viruses mediated by human behavior and immunity. To untangle the complex out-ofphase annual and biennial pattern of three common paramyxoviruses, Respiratory Syncytial Virus (RSV), Human Parainfluenza Virus (HPIV), and Human Metapneumovirus (hMPV), we adopt a theoretical approach that integrates ecological and immunological mechanisms of disease interactions. By estimating parameters from multiyear time series of laboratory-confirmed cases from the intermountain west region of the United States and using statistical inference, we show that models of immune-mediated interactions better explain the data than those based on ecological competition by convalescence. The strength of cross-protective immunity among viruses is correlated with their genetic distance in the phylogenetic tree of the paramyxovirus family.paramyxoviruses | respiratory syncytial viruses | human parainfluenza | pathogen interactions | cross-immunity

show abstract

Parainfluenza Virus Type 3 Expressing the Native or Soluble Fusion (F) Protein of Respiratory Syncytial Virus (RSV) Confers Protection from RSV Infection in African Green Monkeys

Abstract: Respiratory syncytial virus (RSV) causes respiratory disease in young children

Cited by 83 publications

References 39 publications

A serum-free Vero production platform for a chimeric virus vaccine candidate

A serum-free Vero production platform for a chimeric virus vaccine candidate

Potent High-Affinity Antibodies for Treatment and Prophylaxis of Respiratory Syncytial Virus Derived from B Cells of Infected Patients

Cross-immunity between strains explains the dynamical pattern of paramyxoviruses

Contact Info

Product

Resources

About